AG˹ٷ

STOCK TITAN

[8-K] Flowco Holdings Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Celularity Inc. (symbol: CELUW) filed a new Form D reporting a completed Rule 506(b) private placement. The company sold $1.035 million of equity, warrants and the underlying securities to 14 investors, with the first sale on 22 Jul 2025. The entire authorized amount has been placed, leaving $0 remaining; the offering will not last beyond one year and is unrelated to any merger or acquisition. No broker-dealers were engaged, so no sales commissions or finder’s fees were paid. The minimum investment was listed as $0, and the company states that none of the proceeds will be paid to executive officers, directors or promoters named in the filing. Celularity, incorporated in Delaware and operating from Florham Park, NJ, classified itself under the Biotechnology industry group but declined to disclose its revenue range.

Celularity Inc. (simbolo: CELUW) ha presentato un nuovo Modulo D segnalando il completamento di un collocamento privato ai sensi della Regola 506(b). La società ha venduto 1,035 milioni di dollari in azioni, warrant e titoli sottostanti a 14 investitori, con la prima vendita effettuata il 22 luglio 2025. L'intero importo autorizzato è stato collocato, lasciando 0 dollari residui; l'offerta non durerà oltre un anno e non è collegata a fusioni o acquisizioni. Non sono stati coinvolti broker-dealer, quindi non sono state pagate commissioni di vendita o commissioni di intermediazione. L'investimento minimo è stato indicato come 0 dollari e la società afferma che nessuno dei proventi sarà destinato a dirigenti, amministratori o promotori menzionati nella documentazione. Celularity, costituita nel Delaware e con sede operativa a Florham Park, NJ, si è classificata nel settore Biotecnologie ma ha rinunciato a divulgare la fascia di fatturato.

Celularity Inc. (símbolo: CELUW) presentó un nuevo Formulario D reportando la finalización de una colocación privada conforme a la Regla 506(b). La compañía vendió 1.035 millones de dólares en acciones, warrants y valores subyacentes a 14 inversionistas, con la primera venta el 22 de julio de 2025. Se ha colocado la totalidad del monto autorizado, quedando 0 dólares restantes; la oferta no durará más de un año y no está relacionada con ninguna fusión o adquisición. No se contrataron corredores de bolsa, por lo que no se pagaron comisiones de venta ni honorarios de intermediación. La inversión mínima se estableció en 0 dólares y la compañía indica que ninguno de los ingresos será pagado a ejecutivos, directores o promotores mencionados en el informe. Celularity, constituida en Delaware y operando desde Florham Park, NJ, se clasificó dentro del sector dzٱ𳦲ԴDZDzí pero no reveló su rango de ingresos.

Celularity Inc. (심볼: CELUW)� 완료� Rule 506(b) 사모 배정� 보고하는 새로� Form D� 제출했습니다. 사� 1,035� 달러 상당� 주식, 워런� � 기초 증권� 14명의 투자�에게 판매했으�, � 판매� 2025� 7� 22�� 이루어졌습니�. 승인� 전체 금액� 배정되어 남은 금액은 0달러이며, � 제안은 1년을 넘기지 않고 어떤 합병이나 인수와� 관련이 없습니다. 중개업자� 참여하지 않아 판매 수수료나 중개 수수료가 지급되지 않았습니�. 최소 투자 금액은 0달러� 명시되었으며, 사� 수익� � 어느 것도 보고서에 명시� 임원, 이사 또는 홍보자에� 지급되지 않을 �이라� 밝혔습니�. 델라웨어� 설립되어 뉴저지 플로� 파크에서 운영 중인 Celularity� 생명공학(dzٱ𳦳ԴDZDz) 업종으로 분류했으� 매출 범위� 공개하지 않았습니�.

Celularity Inc. (symbole : CELUW) a déposé un nouveau formulaire D signalant une opération de placement privé conforme à la règle 506(b) achevée. La société a vendu pour 1,035 million de dollars d’actions, de bons de souscription et de titres sous-jacents à 14 investisseurs, la première vente ayant eu lieu le 22 juillet 2025. Le montant total autorisé a été entièrement placé, laissant 0 dollar restant ; l’offre ne durera pas plus d’un an et n’est liée à aucune fusion ni acquisition. Aucun courtier n’a été engagé, donc aucune commission de vente ni frais d’intermédiaire n’ont été versés. L’investissement minimum a été fixé à 0 dollar, et la société indique que aucun des produits ne sera versé aux dirigeants, administrateurs ou promoteurs mentionnés dans le dossier. Celularity, constituée dans le Delaware et opérant depuis Florham Park, NJ, s’est classée dans le secteur Biotechnologie mais a refusé de divulguer sa fourchette de revenus.

Celularity Inc. (Symbol: CELUW) hat ein neues Formular D eingereicht, das eine abgeschlossene Privatplatzierung nach Regel 506(b) meldet. Das Unternehmen verkaufte 1,035 Millionen US-Dollar an Aktien, Warrants und zugrunde liegenden Wertpapieren an 14 Investoren, wobei der erste Verkauf am 22. Juli 2025 stattfand. Der gesamte genehmigte Betrag wurde platziert, sodass 0 US-Dollar verbleiben; das Angebot wird nicht länger als ein Jahr dauern und steht in keinem Zusammenhang mit Fusionen oder Übernahmen. Es wurden keine Broker-Dealer beauftragt, daher wurden keine Verkaufsprovisionen oder Vermittlungsgebühren gezahlt. Die Mindestanlage wurde mit 0 US-Dollar angegeben, und das Unternehmen erklärt, dass keiner der Erlöse an Führungskräfte, Direktoren oder Förderer im Formular genannt ausgezahlt wird. Celularity, im Bundesstaat Delaware gegründet und mit Sitz in Florham Park, NJ, ordnete sich der Branche Biotechnologie zu, lehnte jedoch die Angabe der Umsatzspanne ab.

Positive
  • $1.035 million in new capital has already been secured, improving cash resources.
  • No sales commissions or finder’s fees, meaning 100% of proceeds benefit the company.
  • No proceeds directed to insiders, aligning capital use with shareholder interests.
Negative
  • Equity and warrant issuance introduces potential dilution for existing shareholders.
  • Issuer declined to disclose revenue range, limiting financial transparency for investors.

Insights

TL;DR � Small private raise fully closed; neutral impact given size and absence of fees.

Capital & Structure: The $1.035 million raise modestly boosts cash while incurring no placement costs, maximizing net proceeds. Because securities include equity and warrants, future dilution is possible but manageable at this scale.
Governance: Proceeds earmarked away from insiders reduces conflict risk. Filing under Rule 506(b) confines purchasers to accredited investors, limiting disclosure obligations but also restricting liquidity.
Materiality: Relative to typical biotech funding needs, the amount is minor, so balance-sheet impact is limited. Overall, the event is routine and carries neutral valuation implications.

Celularity Inc. (simbolo: CELUW) ha presentato un nuovo Modulo D segnalando il completamento di un collocamento privato ai sensi della Regola 506(b). La società ha venduto 1,035 milioni di dollari in azioni, warrant e titoli sottostanti a 14 investitori, con la prima vendita effettuata il 22 luglio 2025. L'intero importo autorizzato è stato collocato, lasciando 0 dollari residui; l'offerta non durerà oltre un anno e non è collegata a fusioni o acquisizioni. Non sono stati coinvolti broker-dealer, quindi non sono state pagate commissioni di vendita o commissioni di intermediazione. L'investimento minimo è stato indicato come 0 dollari e la società afferma che nessuno dei proventi sarà destinato a dirigenti, amministratori o promotori menzionati nella documentazione. Celularity, costituita nel Delaware e con sede operativa a Florham Park, NJ, si è classificata nel settore Biotecnologie ma ha rinunciato a divulgare la fascia di fatturato.

Celularity Inc. (símbolo: CELUW) presentó un nuevo Formulario D reportando la finalización de una colocación privada conforme a la Regla 506(b). La compañía vendió 1.035 millones de dólares en acciones, warrants y valores subyacentes a 14 inversionistas, con la primera venta el 22 de julio de 2025. Se ha colocado la totalidad del monto autorizado, quedando 0 dólares restantes; la oferta no durará más de un año y no está relacionada con ninguna fusión o adquisición. No se contrataron corredores de bolsa, por lo que no se pagaron comisiones de venta ni honorarios de intermediación. La inversión mínima se estableció en 0 dólares y la compañía indica que ninguno de los ingresos será pagado a ejecutivos, directores o promotores mencionados en el informe. Celularity, constituida en Delaware y operando desde Florham Park, NJ, se clasificó dentro del sector dzٱ𳦲ԴDZDzí pero no reveló su rango de ingresos.

Celularity Inc. (심볼: CELUW)� 완료� Rule 506(b) 사모 배정� 보고하는 새로� Form D� 제출했습니다. 사� 1,035� 달러 상당� 주식, 워런� � 기초 증권� 14명의 투자�에게 판매했으�, � 판매� 2025� 7� 22�� 이루어졌습니�. 승인� 전체 금액� 배정되어 남은 금액은 0달러이며, � 제안은 1년을 넘기지 않고 어떤 합병이나 인수와� 관련이 없습니다. 중개업자� 참여하지 않아 판매 수수료나 중개 수수료가 지급되지 않았습니�. 최소 투자 금액은 0달러� 명시되었으며, 사� 수익� � 어느 것도 보고서에 명시� 임원, 이사 또는 홍보자에� 지급되지 않을 �이라� 밝혔습니�. 델라웨어� 설립되어 뉴저지 플로� 파크에서 운영 중인 Celularity� 생명공학(dzٱ𳦳ԴDZDz) 업종으로 분류했으� 매출 범위� 공개하지 않았습니�.

Celularity Inc. (symbole : CELUW) a déposé un nouveau formulaire D signalant une opération de placement privé conforme à la règle 506(b) achevée. La société a vendu pour 1,035 million de dollars d’actions, de bons de souscription et de titres sous-jacents à 14 investisseurs, la première vente ayant eu lieu le 22 juillet 2025. Le montant total autorisé a été entièrement placé, laissant 0 dollar restant ; l’offre ne durera pas plus d’un an et n’est liée à aucune fusion ni acquisition. Aucun courtier n’a été engagé, donc aucune commission de vente ni frais d’intermédiaire n’ont été versés. L’investissement minimum a été fixé à 0 dollar, et la société indique que aucun des produits ne sera versé aux dirigeants, administrateurs ou promoteurs mentionnés dans le dossier. Celularity, constituée dans le Delaware et opérant depuis Florham Park, NJ, s’est classée dans le secteur Biotechnologie mais a refusé de divulguer sa fourchette de revenus.

Celularity Inc. (Symbol: CELUW) hat ein neues Formular D eingereicht, das eine abgeschlossene Privatplatzierung nach Regel 506(b) meldet. Das Unternehmen verkaufte 1,035 Millionen US-Dollar an Aktien, Warrants und zugrunde liegenden Wertpapieren an 14 Investoren, wobei der erste Verkauf am 22. Juli 2025 stattfand. Der gesamte genehmigte Betrag wurde platziert, sodass 0 US-Dollar verbleiben; das Angebot wird nicht länger als ein Jahr dauern und steht in keinem Zusammenhang mit Fusionen oder Übernahmen. Es wurden keine Broker-Dealer beauftragt, daher wurden keine Verkaufsprovisionen oder Vermittlungsgebühren gezahlt. Die Mindestanlage wurde mit 0 US-Dollar angegeben, und das Unternehmen erklärt, dass keiner der Erlöse an Führungskräfte, Direktoren oder Förderer im Formular genannt ausgezahlt wird. Celularity, im Bundesstaat Delaware gegründet und mit Sitz in Florham Park, NJ, ordnete sich der Branche Biotechnologie zu, lehnte jedoch die Angabe der Umsatzspanne ab.

false000203514900020351492025-08-052025-08-05

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 5, 2025

 

Flowco Holdings Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

 

 

 

 

Delaware

001-42477

99-4382473

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

 

 

 

 

 

1300 Post Oak Blvd., Suite 450

77056

Houston, Texas

(Address of Principal Executive Offices)

(Zip Code)

(713) 997-4877

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Class A Common Stock, $0.0001 par value per share

FLOC

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2025, Flowco Holdings Inc. issued a press release announcing its results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information being furnished pursuant to this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

 

Description

99.1

 

Flowco Holdings Inc. Press Release dated August 5, 2025.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

2


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

FLOWCO HOLDINGS INC.

 

 

By:

 

/s/ Jonathan W. Byers

Name:

 

Jonathan W. Byers

Title:

 

Chief Financial Officer

Date: August 5, 2025

 

3


FLOWCO HLDGS INC

NYSE:FLOC

FLOC Rankings

FLOC Latest News

FLOC Latest SEC Filings

FLOC Stock Data

1.56B
19.78M
22.57%
93.07%
1%
Oil & Gas Equipment & Services
Oil & Gas Field Machinery & Equipment
United States
HOUSTON